DaVita (DVA) AI Stock Analysis

• Market Cap: $8.33B
• Dividend Yield: N/A
• Average Volume (3M): 945.76K
• Price to Earnings (P/E): 12.2
• Beta (1Y): 0.50
• Revenue Growth: 5.14%
• EPS Growth: 4.37%
• Country: US
• Employees: 76,000
• Sector: N/A
• Sector Strength: N/A
• Industry: Medical - Care Facilities
• EPS (TTM): 2.51
• Shares Outstanding: 70,600,000
• 10 Day Avg. Volume: 795,999
• 30 Day Avg. Volume: 945,763
• PEG Ratio: 0.30
• Price to Book (P/B): 104.94
• Price to Sales (P/S): 0.99
• P/FCF Ratio: 8.67
• Enterprise Value/Market Cap: 2.84
• Enterprise Value/Revenue: 1.78
• Enterprise Value/Gross Profit: 5.56
• Enterprise Value/Ebitda: 9.47
• 1Y Price Target: $136.50
• Price Target Upside: 15.74% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4
• EPS Forecast (FY): 10.57
• Revenue Forecast (FY): $13.52B

• Rating: 59 Neutral
• Price Target: $122.00 ▲(3.44% Upside)

DaVita's overall stock score is primarily influenced by its financial performance and technical analysis. The company's moderate revenue growth and strong cash flow are offset by significant challenges in profitability and financial stability. Technical indicators suggest bearish momentum, further impacting the score. Valuation is reasonable, but the lack of a dividend yield is a drawback. The earnings call provides a balanced view, with strategic investments highlighted but also noting operational challenges.

DaVita Business Overview & Revenue Model

Company Description

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

How the Company Makes Money

DaVita generates revenue primarily through its dialysis services, which are reimbursed by Medicare, Medicaid, and commercial insurance providers. The majority of its revenue comes from providing in-center hemodialysis and peritoneal dialysis treatments to patients with kidney disease. Additionally, DaVita earns income from its integrated care services, where it manages the overall care of patients with chronic kidney disease. The company also benefits from strategic partnerships with healthcare providers and payers, allowing it to expand its reach and improve care coordination. These partnerships often enhance reimbursement rates and provide access to a larger patient base, contributing significantly to DaVita's earnings.

DaVita Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

DaVita Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 117.94
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DVA, the sentiment is Negative. The current price of 117.94 is below the 20-day moving average (MA) of 118.66, below the 50-day MA of 121.91, and below the 200-day MA of 135.64, indicating a bearish trend. The MACD of -0.83 indicates Negative momentum. The RSI at 45.54 is Neutral, neither overbought nor oversold. The STOCH value of 43.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DVA.

DaVita Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
ENSG	78 Outperform	$10.16B	31.21	16.98%	0.14%	18.61%	35.76%
THC	74 Outperform	$17.30B	13.50	34.51%	―	-0.56%	-53.50%
HCA	70 Neutral	$107.20B	18.16	―	0.60%	6.82%	15.82%
FMS	65 Neutral	$13.71B	17.25	5.31%	3.34%	4.09%	13.17%
EHC	64 Neutral	$10.87B	20.41	24.94%	0.65%	11.13%	27.53%
DVA	59 Neutral	$8.33B	12.19	―	―	5.14%	4.37%

DaVita Corporate Events

DaVita Amends Credit Agreement for $3.5 Billion Loan

On November 24, 2025, DaVita Inc. amended its Credit Agreement to establish new secured term loan and revolving credit facilities totaling up to $3.5 billion. This financial restructuring aims to refinance existing debt and support general corporate purposes, potentially enhancing DaVita’s financial flexibility and operational capabilities.